Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cue Biopharma, Inc. (CUE) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company (Commission File Number 001-38327), Cue Biopharma uses SEC reports to communicate financial results, material agreements, leadership changes and other significant corporate events.
Investors researching CUE stock can review Form 10-K annual reports and Form 10-Q quarterly reports for detailed information on collaboration revenue, research and development spending, general and administrative expenses, cash and marketable securities, and risk factors related to the development of its Immuno-STAT® platform and pipeline candidates such as CUE-101, CUE-102, CUE-401 and CUE-501.
Form 8-K current reports are particularly relevant for Cue Biopharma, as they document material events including collaboration and license agreements, public offerings under its Form S-3 shelf registration statement, changes in executive leadership, facility lease amendments and key licensing transactions like the collaboration with ImmunoScape for the CUE-100 series. These filings often reference press releases furnished as exhibits, providing additional context on clinical and business developments.
This page also helps users locate information related to equity compensation and executive arrangements, which are described in employment agreements and separation agreements disclosed in 8-K filings. While Cue Biopharma’s insider transactions would appear in Form 4 filings submitted by individual officers and directors, aggregating these documents alongside periodic reports offers a fuller picture of governance and ownership activity.
Stock Titan enhances access to Cue Biopharma’s SEC filings with AI-powered summaries that explain key points from lengthy documents, highlight notable changes from prior periods and surface items that may be important to shareholders. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K and related forms are available promptly, helping users navigate the regulatory record behind CUE stock.
Cue Biopharma, Inc. reports that partner Boehringer Ingelheim has selected its first compound for lead optimization under their April 2025 collaboration focused on differentiated B cell depletion molecules, including Cue’s CUE-501 candidate. This preclinical milestone triggers a $7.5 million payment to Cue Biopharma, which is expected in May 2026.
The company notes that, despite this milestone, it continues to face risks typical for an early-stage biotech, including limited operating history, limited cash, a history of losses, and a current going concern determination about its ability to fund operations beyond the next twelve months.
Cue Biopharma announced a leadership change, appointing Chief Financial and Business Officer Lucinda Warren as Interim President and Chief Executive Officer effective March 27, 2026. She will also retain her finance and business responsibilities and receives a base salary of $525,000 plus a $10,000 monthly interim supplement.
Warren is eligible for an annual bonus up to 45% of base salary and a future stock option equal to about 1.0% of outstanding shares upon achieving a financing milestone. Former CEO Usman Azam resigned on March 26, 2026 and will receive cash severance of $232,500 and up to 12 months of COBRA premium payments under a separation agreement.
Cue Biopharma, Inc. has filed an S-3 registration statement to register up to $300,000,000 of securities, covering debt, common and preferred stock, subscription rights, units and warrants. The filing also includes an at-the-market sales agreement with Jefferies to sell up to $12,666,282 of common stock from time to time.
The prospectus states the ATM agent fee is 3.0% of gross proceeds and cites a public float of $37,998,848 based on March 13, 2026 and 97,283,278 shares held by non-affiliates. The prospectus emphasizes that specific terms for any offering will be set forth in prospectus supplements and warns of the risks described under "Risk Factors."
Cue Biopharma, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on April 13, 2026. The agenda includes electing seven directors for one-year terms, ratifying RSM US LLP as auditor, and an advisory vote on executive compensation.
A key proposal seeks approval to amend the certificate of incorporation to allow a reverse stock split of common shares at a ratio between 1-for-30 and 1-for-50, with exact timing and ratio left to the board’s discretion. The record date is March 9, 2026, when 97,660,791 common shares were outstanding.
Cue Biopharma reported significantly higher collaboration revenue for 2025, driven by a new strategic collaboration and license agreement with ImmunoScape. Collaboration revenue rose to $21.9 million in the fourth quarter from $1.6 million a year earlier and to $27.5 million for the full year from $9.3 million in 2024, leading to fourth quarter net income of $1.6 million and a reduced full-year net loss of $26.6 million compared with $40.7 million in 2024.
The ImmunoScape agreement provides total upfront payments of $15 million, of which Cue received $9.5 million (net of withholding taxes) in the fourth quarter of 2025 and is entitled to an additional $5 million in November 2026, plus a 40% equity stake and eligibility for high-single digit royalties. The company advanced its lead autoimmune candidate CUE-401 toward IND readiness, reporting preclinical toxicology and pharmacology data in which CUE-401 was well tolerated with no adverse events observed and presenting supportive in vivo and in vitro data at a major immune regulation meeting. As of December 31, 2025, Cue Biopharma had $27.1 million in cash and cash equivalents, while continuing to operate at a full-year loss.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing its Immuno-STAT platform to selectively modulate disease-specific T cells, aiming to restore immune balance in autoimmune, inflammatory and oncology indications.
The company’s lead autoimmune candidate, CUE-401, is a bifunctional TGF-β/IL-2 fusion protein designed to expand and induce regulatory T cells and reduce pro‑inflammatory cells. IND‑enabling work and GLP toxicology in mice and non‑human primates are nearing completion, and Cue plans to file an IND in the second quarter of 2026, with initial human safety data expected in the second half of 2026.
The CUE-500 series, including CUE-501, targets pathogenic cells such as autoreactive B cells by redirecting anti‑viral memory T cells and is licensed globally to Boehringer Ingelheim for B‑cell depletion applications. The oncology‑focused CUE-100 series, including CUE‑101 and CUE‑102, has been licensed to ImmunoScape for cell‑therapy applications in solid tumors, providing upfront and milestone economics while Cue retains non‑oncology rights for a period.
Cue operates under a core technology license from Albert Einstein College of Medicine, with royalties and up to $1.85M in milestones per product and $5.75M tied to cumulative sales, and has additional collaborations with LG Chem and ImmunoScape. The company reports recurring operating losses, no approved products, a substantial doubt about its ability to continue as a going concern, and warns it will require substantial additional financing and successful partnerships to advance its pipeline.
Cue Biopharma will hold its 2026 annual meeting of stockholders virtually on April 13, 2026 at 9:00 a.m. Eastern Time. Agenda items include the election of seven directors, ratification of RSM US LLP as auditor, a non-binding advisory vote on executive compensation and a proposed reverse stock split at a ratio between 1-for-30 and 1-for-50 with the exact ratio and timing to be determined by the board.
Stockholders of record as of the close of business on March 9, 2026 may vote online at www.virtualshareholdermeeting.com/CUE2026. Proxy materials and the 2025 Annual Report (Form 10-K) will be mailed and posted on or about March [__], 2026.
Cue Biopharma, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 13, 2026. The company explains how stockholders can submit proposals or director nominations for that meeting and the deadlines that apply.
Stockholder proposals intended for inclusion in the company’s proxy materials under SEC Rule 14a-8 must be received at Cue Biopharma’s Boston headquarters by February 28, 2026, which the company considers a reasonable time before it begins printing and mailing proxy materials. For other business or director nominations to be brought directly before the meeting under the company’s Amended and Restated Bylaws, notice must also be received by February 28, 2026, or the later of 90 days before the meeting and 10 days after public announcement of the meeting date.
The company notes that stockholders who plan to solicit proxies in favor of their own director nominees, rather than the company’s nominees, and who seek to comply with the SEC’s universal proxy rule (Rule 14a-19), must likewise provide the required notice by February 28, 2026. If a stockholder misses these deadlines, the board’s named proxies may exercise discretionary voting authority on that stockholder’s proposal at the 2026 Annual Meeting.